Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Drilon

Showing results (221-230 of 269) with videos related to

Pageof 27
Sort By:
Cancer Discovery|April 4, 2018
Response to ERBB3-Directed Targeted Therapy in <i>NRG1</i>-Rearranged CancersAlexander Drilon, Romel Somwar, Biju P Mangatt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2026
Molecular lineages of sporadic mismatch-repair deficient colorectal cancerMichael B Foote, Guilherme Harada, Somer Abdelfattah, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 21, 2025
eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancerJacob A Boyer, Ezra Y Rosen, Malvika Sharma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2021
Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular SubtypesJason C Chang, Michael Offin, Christina Falcon, et al.
JAMA Oncology|November 27, 2024
Next-Generation Sequencing for HLA Genotype Screening and Matching to HLA-Restricted TherapiesMichael V Gormally, Monica F Chen, Anne Marie Noronha, et al.
Cancer Discovery|June 3, 2023
SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted TherapyAlexander Drilon, Manish R Sharma, Melissa L Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2018
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket TrialBob T Li, Ronglai Shen, Darren Buonocore, et al.
Cancer Discovery|December 13, 2022
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance MutationsAlexander Drilon, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2026
The Genomic Landscape of MYC, MYCL, and MYCN Amplified Solid TumorsMatteo Repetto, Allison L Richards, Monica F Chen, et al.
Cancer Discovery|September 13, 2024
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound MutationsJessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Pageof 27

Showing results (221-230 of 269) with videos related to

Sort By:
Pageof 27
Cancer Discovery|April 4, 2018
Response to ERBB3-Directed Targeted Therapy in <i>NRG1</i>-Rearranged CancersAlexander Drilon, Romel Somwar, Biju P Mangatt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2026
Molecular lineages of sporadic mismatch-repair deficient colorectal cancerMichael B Foote, Guilherme Harada, Somer Abdelfattah, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 21, 2025
eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancerJacob A Boyer, Ezra Y Rosen, Malvika Sharma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2021
Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular SubtypesJason C Chang, Michael Offin, Christina Falcon, et al.
JAMA Oncology|November 27, 2024
Next-Generation Sequencing for HLA Genotype Screening and Matching to HLA-Restricted TherapiesMichael V Gormally, Monica F Chen, Anne Marie Noronha, et al.
Cancer Discovery|June 3, 2023
SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted TherapyAlexander Drilon, Manish R Sharma, Melissa L Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2018
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket TrialBob T Li, Ronglai Shen, Darren Buonocore, et al.
Cancer Discovery|December 13, 2022
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance MutationsAlexander Drilon, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2026
The Genomic Landscape of MYC, MYCL, and MYCN Amplified Solid TumorsMatteo Repetto, Allison L Richards, Monica F Chen, et al.
Cancer Discovery|September 13, 2024
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound MutationsJessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Pageof 27